I wouldn't say it was a "mistake", probably more of a learning curve for the management, as they have now learned that A LOT of shareholders would just want them to commercialise the IP they already have and I think they will now just put their foot down towards that. It's like, they now know what the market wants, so they will just deliver now
And yup, mentioned above, next week should be a good week for shareholders, although I do expect a slight pull back, not much though. And should keep continuing north from here.
"We are back where we were before the CR", somewhat, yes. But I feel we are in a much better position than we are before the CR. Since management KNOWS what they need to do to keep shareholders happy. And seems that HepaFat has advanced a fair bit since 2 months ago and that we received a fairly positive detailed update on HepaFat.
Not trying to ramp, but I feel good about this
RHT Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
